Tropical medicine and infectious disease · 2025
Mycoplasma genitalium Infections and Associated Antimicrobial Resistance in Canada, 1980-2023.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Copete Angela, Herrera Mariana, Suarez-Ariza Camilo, Gitau Zipporah, Arango-Uribe Maria, Keynan Rotem, Oda Camila, Singh Ameeta E, Skinner Stuart, Spence Cara, Riaño Will, MacKenzie Lauren J, Kasper Ken, Ireland Laurie, Martin Irene, Bullard Jared, Lopez Lucelly, Marin Diana, Haworth-Brockman Margaret, Keynan Yoav, Rueda Zulma Vanessa
Аннотация
BACKGROUND: We aimed to describe trends in M. genitalium prevalence and associated resistance in Canada between 1980 and 2022.
METHODS: Ecological study and a scoping review. We collected publicly available data published by the governments of all Canadian provinces and territories. We also systematically searched PubMed, Medline, Embase, and grey literature using the keywords 'M. genitalium', 'Canada', and all provinces and territories. We reported M. genitalium prevalence, age, sex, gender, symptoms, coinfections, sample types used for diagnosis, and macrolide and fluoroquinolone resistance rates.
RESULTS: National or provincial surveillance systems for M. genitalium are absent. Eight studies reported the epidemiology of M. genitalium. The prevalence ranged between 3% in Quebec and 30.3% in Ontario. Half of the patients reported symptoms. The most collected sample for M. genitalium diagnosis was urine, followed by cervical and urethral swabs. Co-infection with Chlamydia trachomatis was reported in 3.3% to 16.4% of cases and with Neisseria gonorrhoeae in 0.0% to 24.0%. Macrolide resistance ranged between 25% and 82.1%, and fluoroquinolone resistance between 0.0% and 29.1%.
CONCLUSIONS: M. genitalium prevalence and resistance rates varied by sex, gender, province, and specimen type. In the absence of routine surveillance, incomplete data hinders understanding the bacterium's natural history, its impact on some key groups, and the tracking of antibiotic resistance.
METHODS: Ecological study and a scoping review. We collected publicly available data published by the governments of all Canadian provinces and territories. We also systematically searched PubMed, Medline, Embase, and grey literature using the keywords 'M. genitalium', 'Canada', and all provinces and territories. We reported M. genitalium prevalence, age, sex, gender, symptoms, coinfections, sample types used for diagnosis, and macrolide and fluoroquinolone resistance rates.
RESULTS: National or provincial surveillance systems for M. genitalium are absent. Eight studies reported the epidemiology of M. genitalium. The prevalence ranged between 3% in Quebec and 30.3% in Ontario. Half of the patients reported symptoms. The most collected sample for M. genitalium diagnosis was urine, followed by cervical and urethral swabs. Co-infection with Chlamydia trachomatis was reported in 3.3% to 16.4% of cases and with Neisseria gonorrhoeae in 0.0% to 24.0%. Macrolide resistance ranged between 25% and 82.1%, and fluoroquinolone resistance between 0.0% and 29.1%.
CONCLUSIONS: M. genitalium prevalence and resistance rates varied by sex, gender, province, and specimen type. In the absence of routine surveillance, incomplete data hinders understanding the bacterium's natural history, its impact on some key groups, and the tracking of antibiotic resistance.